Prognostic Value of Anti-Ro52 Antibodies in Connective Tissue Diseases (a-Ro52)

Central Hospital, Nancy, France

Status: Unknown

Conditions: Connective Tissue Diseases

Treatments: Other: Follow-up

Study type: Observational

Funder types: Other

Identifiers

NCT03565601

PSS2018/AR052-DECKER/MS

Details and patient eligibility

About

Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.

Enrollment: 400 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Connective tissue disease (differenciated or not)
• Presence of anti-Ro52 antibodies at diagnosis

Exclusion criteria

• Healthy subjects

Trial design

400 participants in 2 patient groups

CTD patients with anti-Ro52 antibodies

Description:

Connective tissue disease patients with anti-Ro52 antibodies at diagnosis

Treatment:

Other: Follow-up

CTD patients without anti-Ro52 antibodies

Description:

Connective tissue disease patients without anti-Ro52 antibodies at diagnosis

Treatment:

Other: Follow-up